VIR Q4 2023 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M-66.0% YoY

Gross Profit

-$90M-533.6% margin

Operating Income

-$139M-828.1% margin

Net Income

-$116M-690.9% margin

EPS (Diluted)

$-0.86

QoQ Revenue Growth

+536.1%

Cash Flow

Operating Cash Flow

-$108M

Free Cash Flow

-$109M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$329M

Stockholders' Equity

$1.6B

Cash & Equivalents

$242M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$49M	-66.0%
Gross Profit	-$90M	-$112M	+19.8%
Operating Income	-$139M	-$151M	+7.6%
Net Income	-$116M	-$102M	-14.1%

Revenue Segments

Grant

$23M97%

Contract Revenue

$744,0003%